Home Enzolytics

Enzolytics

In operation
-
Developer of Biologics for the Treatment of Debilitating Infectious Diseases
Basic
Enterprise Profile

Basic Information

Enzolytics is a drug development company dedicated to using its proprietary proteins for the treatment of debilitating infectious diseases, creating medications that improve human health. Enzolytics, Inc.'s flagship compound ITV-1 is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown to be effective in treating HIV. ITV-1 has been proven to modulate the immune system. IPF is a platform technology with potential for widespread application. It does not exhibit the major neurological, gastrointestinal, and hematological side effects found in currently used antiretroviral drugs. IPF has not demonstrated antiviral resistance and is cost-effective.
Enzolytics, Inc.
Liberia
unclear
--
info@enzolytics.com

Enterprise Profile

Industrial Sector
New Drug Development Biological Drug Production
Technology
Immunological Techniques Protein Technology
Concept
Infectious Diseases Department Disease Treatment Infectious Diseases
Application Scenarios
Innovative Drugs Prescription Drug Monoclonal Antibody Recombinant Protein